Key Highlights

  • Karyopharm Therapeutics (NASDAQ:KPTI) led the retreat with a 34.75% slide to USD 0.0261, following its Chapter 11 filing and a Nasdaq trading suspension that starts at the open on November 11, 2026. Exagen (NASDAQ:XGN) gave up 25.99% and ended at USD 5.26.
  • TriSalus Life Sciences (NASDAQ:TLSI) shed 23.76% to USD 2.46 once its full-year Revenue range was revised to USD 46 million to USD 48 million. CDT Equity (NASDAQ:CDT) lost 23.52% to USD 0.6425 in the wake of a reverse split.
  • Curis (NASDAQ:CRIS) slipped 17.50% to USD 0.5755 with no fresh catalyst found, prolonging a decline that started after a November 6 filing flagged a possible Nasdaq delisting.
  • Relative Volume across the five ran between 0.02 and 4.11, while market values spanned USD 591.99 thousand to USD 151.17 million, so scarce trading and listing worries helped drive several of the drops.

Karyopharm Therapeutics (NASDAQ:KPTI): Down 34.75% on Chapter 11 and a Delisting Notice

Karyopharm Therapeutics finished at USD 0.0261, a 34.75% decline from a calculated prior close of USD 0.0400. Bankruptcy proceedings, rather than any new Tuesday news, explain the move. The company and KPT Texas LLC submitted Chapter 11 petitions on November 2, 2026, and an 8-K signed November 5 reported that Nasdaq sent a delisting notice on November 4, that trading halts at the open on November 11, 2026, and that holders of common and Series A preferred stock should expect no distribution. Quotes on the OTC market are anticipated under KPTIQ. As general context, funds barred from owning Delisted securities frequently become forced sellers, which tends to weigh on prices. Volume reached 4.59 million shares at a relative volume of 0.14, roughly USD 0.12 million traded (calculated). Against a USD 591.99 thousand Market Value sits earlier published Debt near USD 328.53 million. Few trades can swing Karyopharm Therapeutics (NASDAQ:KPTI), and the chief danger is a complete loss for common shareholders.

Exagen (NASDAQ:XGN): Down 25.99% on Third-Quarter Results and Unchanged Guidance

Exagen ended at USD 5.26, off 25.99% from a calculated prior close of USD 7.11, a drop near USD 1.85 on the day it released third-quarter figures. Revenue came in at USD 18.4 million, a 7% increase from USD 17.2 million, while the net loss narrowed to USD 6.3 million from USD 7.1 million and gross Margin improved to 58.8%. Guidance for 2026 stayed at USD 72 million to USD 75 million, not raised, which points to fourth-quarter revenue of roughly USD 16.3 million to USD 19.3 million (calculated). Published coverage does not say which element of the release triggered the selling, so any connection is an inference. Trading volume was 567,840 shares at a relative volume of 1.40. The USD 127.3 million market value equals about 1.7 times the guidance midpoint (calculated), with cash at USD 28.1 million. Persistent losses, test reimbursement and price swings are risks for Exagen (NASDAQ:XGN), and the 52-week range could not be confirmed.

TriSalus Life Sciences (NASDAQ:TLSI): Down 23.76% on Third Quarter Results and Revised Guidance

TriSalus Life Sciences ended at USD 2.46, a 23.76% decrease from a calculated prior close of USD 3.23. Its third quarter Earnings release went out in an 8-K dated November 10, 2026, yet it is unclear whether the news landed before the open, mid-session or after the close, so tying it to the decline is an inference. Revenue of USD 12.9 million grew 11.3%, and the 2026 outlook was revised to USD 46 million to USD 48 million. With nine-month revenue at USD 33.2 million, the final quarter must produce USD 12.8 million to USD 14.8 million (calculated). Volume came to 623.61K shares at a relative volume of 4.11. The USD 151.17 million market value squares with 61,659,370 shares, and cash stood at USD 41.1 million versus a quarterly net loss of USD 8.9 million. A further equity raise with dilution is a risk for TriSalus Life Sciences (NASDAQ:TLSI), and a handful of trades can shift the price.

CDT Equity (NASDAQ:CDT): Down 23.52% After a 1-for-20 Reverse Stock Split

CDT Equity settled at USD 0.6425, a 23.52% decline from a calculated prior close of USD 0.84, during the third session after a 1-for-20 reverse split became effective at 5:00 p.m. ET on November 5, 2026. Outstanding shares dropped from 20,357,283 to roughly 1,017,864. No results, guidance or other news dated November 9 or 10 turned up. As general context, a split lifts the quoted price twentyfold and cuts the share count by the same Factor without altering what a holding is worth, and trading after such an event is often choppy. The USD 653.98 thousand market value matches the new share count. Volume of 348.86K shares at a relative volume of 0.07 equals about 34.3% of shares outstanding (calculated). The EPS print of USD -2,834,501.10 looks like a display glitch. The price sits roughly 35.8% beneath USD 1.00, a Nasdaq minimum bid reference, which is a risk for CDT Equity (NASDAQ:CDT), and spreads can widen.

Curis (NASDAQ:CRIS): Down 17.50% on No New Catalyst Identified

Curis finished at USD 0.5755, a 17.50% slide from a calculated prior close of USD 0.6976. Published coverage turned up no company release or filing dated November 9 or 10, 2026. On November 6 the shares closed at USD 0.9065 and then dropped 13.73% after hours, and a filing cautioned that delisting might follow with no compliance period once the stock spends 30 days under USD 1.00. The close stands 42.5% below the USD 1.00 minimum bid (calculated). A private Placement of about USD 8.5 million placed 16,666,680 shares or pre-funded warrants at an effective USD 0.51 apiece, and as general context, prices often gravitate toward a financing level when the Supply of shares is heavy. Volume of 480,790 shares was merely 0.02 times the average, and the market value is near USD 3.84 million (calculated). A reverse split vote is scheduled for November 18 and results for November 12. A few trades can move Curis (NASDAQ:CRIS).

Where Things Stand

Karyopharm Therapeutics (NASDAQ:KPTI) was the heaviest faller among healthcare market movers at -34.75%, and what ties the five together is listing strain, post-split trading and disappointing results in small, lightly traded names. The lists use a published screener snapshot of the regular session on November 10, 2026. Big one-day swings in thin stocks can reverse the next session since only a few trades set the price. Exagen (NASDAQ:XGN) declined around its results, as did TriSalus Life Sciences. CDT Equity (NASDAQ:CDT) dropped following its split, while Curis slid with no catalyst identified.